FAM104A

Mutation & survival
SurvivalMutationKaplan–Meier · TCGA cohorts

Across TCGA pan-cancer cohorts, FAM104A Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated FAM104A data layer compared with 25 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher FAM104A Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated FAM104A expression acts as an unfavorable survival marker.

CESC and PRAD are the cancer types where FAM104A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.
LineageMeasureSplitStageAUC1
high
AUC2
low
pSampling consensus
CESCDFSMedianII,III,IV0.1930.705.0456view →
PRADDFSMedianAll0.0850.774<.0016view →
Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

FAM104A–CESC (DFS)

Kaplan–Meier survival curve for FAM104A mutant vs wild-type samples in CESC.

Open the CESC breakdown →

Exploration